#1 Clinical Trials Search in Europe

Darovasertib

Darovasertib, also known as IDE196 or LXS196, is an oral medication being studied in clinical trials for the treatment of ocular melanoma, particularly uveal melanoma. This drug is a potent, selective inhibitor of Protein Kinase C and is being investigated as a potential neoadjuvant and adjuvant therapy for patients with this rare form of eye cancer. The ongoing trials aim to evaluate the safety, efficacy, and potential benefits of Darovasertib in improving outcomes for patients with ocular melanoma.

Table of Contents

What is Darovasertib?

Darovasertib, also known as IDE196 or LXS196, is a new drug being studied for the treatment of ocular melanoma, a rare type of eye cancer[1]. It is an oral medication that works by targeting specific proteins in cancer cells[2].

What Condition Does Darovasertib Target?

Darovasertib is primarily being investigated for the treatment of uveal melanoma, which is a type of ocular melanoma. Uveal melanoma is a cancer that develops in the uvea, the middle layer of the eye that includes the iris, ciliary body, and choroid[1][2].

How Does Darovasertib Work?

Darovasertib is described as a potent, selective inhibitor of Protein Kinase C. This means it works by blocking the action of certain proteins (protein kinases) that are involved in cancer cell growth and survival. By inhibiting these proteins, Darovasertib may help to slow down or stop the growth of uveal melanoma tumors[1].

How is Darovasertib Administered?

Darovasertib is an oral medication, which means it is taken by mouth. In current clinical trials, patients typically take Darovasertib tablets twice daily. The starting dose in one study is 300mg twice a day, but this may vary depending on the specific trial and patient needs[2].

Current Clinical Trials

There are currently two main clinical trials investigating Darovasertib for ocular melanoma:

  1. A Phase 2 multi-center open-label study for patients with primary uveal melanoma. This trial is looking at using Darovasertib before and after primary treatment (either eye removal surgery or radiation therapy)[1].

  2. A neoadjuvant/adjuvant trial for patients with high-risk uveal melanoma who are planned to undergo eye removal surgery (enucleation)[2].

These trials aim to assess the safety, effectiveness, and potential benefits of Darovasertib in different stages of uveal melanoma treatment.

Potential Benefits of Darovasertib

The ongoing clinical trials are investigating several potential benefits of Darovasertib:

  • Tumor shrinkage: Researchers are measuring whether Darovasertib can reduce the size of uveal melanoma tumors before surgery or radiation therapy[1][2].

  • Eye preservation: For some patients, Darovasertib might help avoid the need for eye removal surgery by shrinking the tumor enough to allow for radiation therapy instead[1].

  • Reduced radiation exposure: In patients receiving radiation therapy, Darovasertib might help reduce the amount of radiation needed, potentially leading to fewer side effects[1].

  • Prevention of disease recurrence and spread: The trials are also looking at whether Darovasertib can help prevent the cancer from coming back or spreading to other parts of the body[1][2].

Safety and Side Effects

As with any new medication, understanding the safety profile and potential side effects of Darovasertib is a crucial part of the ongoing clinical trials. Researchers are carefully monitoring patients for any adverse events (side effects) that may occur during treatment[1][2].

The trials are specifically looking at:

  • The types and severity of side effects
  • How many patients experience side effects
  • Whether side effects lead to changes in treatment or stopping the medication
  • Any serious adverse events
  • Changes in laboratory test results

It’s important to note that the full safety profile of Darovasertib is still being determined through these clinical trials.

Future Prospects and Long-term Follow-up

The clinical trials for Darovasertib include long-term follow-up periods to assess its effectiveness over time. Researchers will be monitoring patients for up to 3 years after treatment to evaluate:

  • Visual outcomes: How well patients maintain their vision after treatment[1].

  • Disease recurrence: Whether the cancer comes back after initial treatment[1][2].

  • Metastatic disease: If the cancer spreads to other parts of the body[1].

  • Overall survival: How long patients live after starting treatment[1].

These long-term studies will provide valuable information about the potential of Darovasertib as a treatment for uveal melanoma and help determine its role in future treatment strategies for this rare but serious eye cancer.

Aspect Details
Drug Name Darovasertib (also known as IDE196 or LXS196)
Type of Drug Oral, potent, selective inhibitor of Protein Kinase C
Condition Studied Ocular Melanoma (specifically Uveal Melanoma)
Treatment Settings Neoadjuvant and Adjuvant
Dosage 300 mg tablets, twice daily
Primary Outcomes Safety, tolerability, tumor response, eye salvage rate
Secondary Outcomes Visual acuity, local recurrence, metastatic disease, overall survival
Treatment Duration Varies by trial: 56 days to 12 months (6 months neoadjuvant + 6 months adjuvant)
Follow-up Period Up to 3 years post-treatment

FAQ

  • What is Darovasertib? Darovasertib is an oral medication that selectively inhibits Protein Kinase C. It is being studied as a potential treatment for ocular melanoma, particularly uveal melanoma, which is a rare form of eye cancer.
  • How is Darovasertib administered in clinical trials? In the clinical trials, Darovasertib is typically administered orally as 300 mg tablets taken twice daily. The duration of treatment varies depending on the specific trial and patient response.
  • What are the main goals of the Darovasertib clinical trials? The main goals of these trials are to assess the safety and tolerability of Darovasertib, evaluate its effects on tumor size, determine its potential to prevent disease recurrence, and explore its impact on patient survival and quality of life.
  • What is neoadjuvant and adjuvant therapy? Neoadjuvant therapy is treatment given before the main treatment (such as surgery), while adjuvant therapy is treatment given after the main treatment. In these trials, Darovasertib is being studied in both neoadjuvant and adjuvant settings for ocular melanoma patients.
  • How long do patients typically receive Darovasertib in these trials? The duration of treatment varies between trials. Some patients receive Darovasertib for up to 6 months in the neoadjuvant setting, followed by an additional 6 months in the adjuvant setting. Other trials may have shorter treatment periods, such as 56 days, to assess initial safety and tolerability.

Ongoing Clinical Trials on Darovasertib

  • A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +4

  • Study of Darovasertib and Crizotinib for Patients with Metastatic Uveal Melanoma Who Are HLA-A2 Negative

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study of Darovasertib and Crizotinib for Patients with HLA-A2 Negative Metastatic Uveal Melanoma

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study of Darovasertib for Patients with Localized Uveal Melanoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands

Glossary

  • Uveal Melanoma: A rare type of eye cancer that develops in the uvea, which is the middle layer of the eye containing the iris, ciliary body, and choroid.
  • Neoadjuvant Therapy: Treatment given before the main treatment, typically to shrink a tumor before surgery or radiation therapy.
  • Adjuvant Therapy: Additional treatment given after the main treatment to lower the risk of the cancer coming back.
  • Enucleation: Surgical removal of the entire eye.
  • Plaque Brachytherapy: A type of radiation therapy where a small radioactive seed is placed directly on the eye to treat the tumor.
  • Protein Kinase C: An enzyme involved in various cellular processes, including cell growth and division, which can be overactive in some cancers.
  • CTCAE: Common Terminology Criteria for Adverse Events, a set of criteria used to evaluate the safety of drugs in clinical trials.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacodynamics: The study of how a drug affects the body.
  • Pharmacokinetics: The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.

References